Stock Information

• HC Wainwright & Co. Reiterates Buy on Ionis Pharmaceuticals, Maintains $100 Price Target
  Thu, Sep 24, 2026 6:59 AM
• The Biggest Losers In Biotech — And It Had Nothing To Do With 'Compelling,' 'Best-In-Disease' Data
  Wed, Sep 23, 2026 8:12 PM
• Roche, Ionis RNA drug scores in kidney disease study
  Wed, Sep 23, 2026 4:21 PM
• Ionis Delivers Positive Late-Stage Results for Two Partnered Drugs
  Wed, Sep 23, 2026 4:13 PM
• Ionis and Roche Advance First RNA-Targeted Therapy for Autoimmune Kidney Disease
  Wed, Sep 23, 2026 12:13 PM
• Ionis announces positive interim data from partner Roche’s Phase 3 IMAgINATION study in IgA nephropathy (IgAN)
  Wed, Sep 23, 2026 5:00 AM
• Ionis Pharmaceuticals And Partner Roche Said Prespecified Interim Results From Phase 3 IMAgINATION Study Of Sefaxersen For Primary IgA Nephropathy Met Its Primary Endpoint Of Statistically Significant And Clinically Meaningful Improvements In Proteinuria Reduction Vs. Placebo At 37 Weeks
  Wed, Sep 23, 2026 4:51 AM
• Ionis to Seek Expedited FDA Review for ALS Drug
  Tue, Sep 22, 2026 12:11 PM
• Ionis announces positive topline results from Phase 3 FUSION study of ulefnersen marking significant milestone in advancing first potential disease modifying treatment for FUS-ALS
  Tue, Sep 22, 2026 12:00 PM
• Beyond Meta, Cathie Wood’s ARKG Loads Up On These 4 Biotech Names
  Tue, Sep 22, 2026 11:10 AM

Financial data not available